Home/Filings/3/0001192482-19-000388
3//SEC Filing

Quaker BioVentures II LP 3

Accession 0001192482-19-000388

CIK 0001561921other

Filed

Nov 6, 7:00 PM ET

Accepted

Nov 7, 9:05 PM ET

Size

11.0 KB

Accession

0001192482-19-000388

Insider Transaction Report

Form 3
Period: 2019-11-07
Holdings
  • Series A Preferred Stock

    Common Stock (345,489 underlying)
  • Common Stock

    29,288
  • Series B Preferred Stock

    Common Stock (516,947 underlying)
  • Warrant

    Exercise: $1.16From: 2017-01-18Exp: 2027-01-18Series B Preferred Stock (446,813 underlying)
Holdings
  • Common Stock

    29,288
  • Series A Preferred Stock

    Common Stock (345,489 underlying)
  • Series B Preferred Stock

    Common Stock (516,947 underlying)
  • Warrant

    Exercise: $1.16From: 2017-01-18Exp: 2027-01-18Series B Preferred Stock (446,813 underlying)
Footnotes (4)
  • [F1]These securities are owned of record by Quaker BioVentures II, L.P. ("Quaker"). Quaker BioVentures Capital II, L.P. ("Quaker Capital") is the general partner of Quaker, has voting and dispositive power over the securities held by Quaker, and thus may be deeemd to beneficially own these securities. Voting and investment determinations made by Quaker Capital with respect to the securities held by Quaker are made by an investment committee of Quaker Partners. Quaker Capital disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.
  • [F2]Shares of Series A and Series B Preferred Stock (collectively, the "Preferred Stock") have no expiration date and are convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). The shares of Preferred Stock will automatically convert into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment in cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.
  • [F3]Shares of Series A Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate.
  • [F4]Shares of Series B Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate.

Issuer

TELA Bio, Inc.

CIK 0001561921

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001497725

Filing Metadata

Form type
3
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 9:05 PM ET
Size
11.0 KB